Entera Bio Stock Performance
| ENTX Stock | USD 1.95 0.07 3.72% |
The firm shows a Beta (market volatility) of 0.58, which means possible diversification benefits within a given portfolio. As returns on the market increase, Entera Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Entera Bio is expected to be smaller as well. At this point, Entera Bio has a negative expected return of -0.0505%. Please make sure to confirm Entera Bio's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Entera Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Entera Bio is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Entera Bio Shares Up 1.1 percent - Time to Buy - MarketBeat | 01/06/2025 |
2 | Acquisition by Yaacov-garbeli Dana of 130000 shares of Entera Bio at 1.99 subject to Rule 16b-3 | 01/10/2025 |
3 | Acquisition by Ellis Sean of 28509 shares of Entera Bio at 2.28 subject to Rule 16b-3 | 01/15/2025 |
4 | Entera Bio Ltd. Sees Significant Decrease in Short Interest - MarketBeat | 01/16/2025 |
5 | Acquisition by Lieberman Gerald M of 28509 shares of Entera Bio at 2.28 subject to Rule 16b-3 | 01/17/2025 |
6 | Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan | 01/27/2025 |
7 | Is Entera Bio In A Good Position To Deliver On Growth Plans | 02/06/2025 |
8 | EFFECTS OF EB613 TABLETS ORAL PTH ON TRABECULAR AND CORTICAL BONE USING 3D-DXA POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congr... | 02/19/2025 |
9 | Acquisition by Ellis Sean of 89041 shares of Entera Bio subject to Rule 16b-3 | 03/04/2025 |
10 | Acquisition by Ellis Sean of 40000 shares of Entera Bio at 0.6 subject to Rule 16b-3 | 03/07/2025 |
11 | Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview - TradingView | 03/10/2025 |
12 | OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1Glucagon ... | 03/17/2025 |
| Begin Period Cash Flow | 12.4 M |
Entera |
Entera Bio Relative Risk vs. Return Landscape
If you would invest 216.00 in Entera Bio on December 19, 2024 and sell it today you would lose (21.00) from holding Entera Bio or give up 9.72% of portfolio value over 90 days. Entera Bio is currently does not generate positive expected returns and assumes 5.1111% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Entera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entera Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entera Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Entera Bio, and traders can use it to determine the average amount a Entera Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0099
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENTX |
Estimated Market Risk
| 5.11 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Entera Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entera Bio by adding Entera Bio to a well-diversified portfolio.
Entera Bio Fundamentals Growth
Entera Stock prices reflect investors' perceptions of the future prospects and financial health of Entera Bio, and Entera Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entera Stock performance.
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | (71.93) % | ||||
| Current Valuation | 64.11 M | ||||
| Shares Outstanding | 36.83 M | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 10.96 X | ||||
| Price To Sales | 725.48 X | ||||
| Revenue | 14 K | ||||
| Gross Profit | 9 K | ||||
| EBITDA | (8.8 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 390 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.89 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (7.31 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 71.82 M | ||||
| Total Asset | 11.77 M | ||||
| Retained Earnings | (104.39 M) | ||||
| Working Capital | 10.17 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
About Entera Bio Performance
Evaluating Entera Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Entera Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entera Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.2 K | -1.2 K | |
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.96) | (1.01) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (0.98) | (1.03) |
Things to note about Entera Bio performance evaluation
Checking the ongoing alerts about Entera Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entera Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entera Bio generated a negative expected return over the last 90 days | |
| Entera Bio has high historical volatility and very poor performance | |
| Entera Bio may become a speculative penny stock | |
| The company reported the previous year's revenue of 14 K. Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 9 K. | |
| Entera Bio currently holds about 17.28 M in cash with (7.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Entera Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1Glucagon ... |
- Analyzing Entera Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entera Bio's stock is overvalued or undervalued compared to its peers.
- Examining Entera Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entera Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entera Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entera Bio's stock. These opinions can provide insight into Entera Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.